• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Terran Biosciences, Pierre Fabre Ink Exclusive Licensing Deal for Idazoxan

    ASM Research Chemicals Launches Development Packs for API Manufacturing

    WuXi Increases Manufacturing Capacity in Germany

    Quanticate, KPS Life Partner to Advance Clinical Research

    Sterling Joins Partnership to Advance AI Flow Chemistry Techniques
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    ASM Research Chemicals Launches Development Packs for API Manufacturing

    WuXi Increases Manufacturing Capacity in Germany

    Early CMC Strategies to Support Late-Stage Success

    Sterling Joins Partnership to Advance AI Flow Chemistry Techniques

    Innovent Enters into Clinical Trial Collaboration with Merck KGaA
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Serialization and the War on Counterfeit Drugs

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Terran Biosciences, Pierre Fabre Ink Exclusive Licensing Deal for Idazoxan

    Early CMC Strategies to Support Late-Stage Success

    Quanticate, KPS Life Partner to Advance Clinical Research

    MilliporeSigma Invests €35M in Biosafety Testing in Scotland

    Dragonfly Therapeutics Expands Clinical Leadership Team
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Regulatory Affairs: Accelerating Drug Development Timelines

    Berkshire Sterile Secures Over $230,000 in Training Grants

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene International Ltd.

    TaiMed Biologics

    Almac Group

    Quotient Sciences

    LOTTE BIOLOGICS
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene International Ltd.

    TaiMed Biologics

    Almac Group

    Quotient Sciences

    LOTTE BIOLOGICS
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Pharmaceutical Recall Trends to Watch in 2023

    2022 was a record-breaking year for the number of units recalled, up 114% over 2021.

    Pharmaceutical Recall Trends to Watch in 2023
    Kristin Brooks, Managing Editor, Contract Pharma03.31.23
    In 2022, the pharmaceutical industry saw the most units recalled than in the past six years, with 567.3 million, a 114% increase over the 264.6 million units recalled in 2021, according to new data from the recent Sedgwick 2023 State of the Nation Recall Index report.1
     
    The report provides insight and analysis for mitigating recall risk along with key perspectives on past and present recall data and product safety trends. The index also shares insights and guidance into the economic, regulatory and legal developments shaping product safety in the pharmaceutical sector.
     
    As supply chains become more diverse, and regulatory environments more complex, companies face increased liability, if proper measures are not taken. Chris Harvey, Senior Vice President, Sedgwick brand protection, discusses findings from the Recall Index report, including 2022 recall data, what it means for the pharmaceutical industry, and predictions for 2023.  –KB 
     
    Contract Pharma: What do you anticipate the FDA’s top product safety priorities will be in 2023?
     
    Chris Harvey: The Biden Administration released the Fall 2022 Unified Agenda of Regulatory and Deregulatory Actions in January 2023. The FDA listed 74 short-term actions and 13 long-term actions across all FDA-regulated product categories including drugs, biologics, dietary supplements, and tobacco products. We can expect the agency to continue its aggressive stance on tobacco products and closer monitoring of supplements in 2023.
     
    We also anticipate guidance and further clarification on the new Food and Drug Omnibus Reform Act of 2022 (FDORA), the Modernization of Cosmetics Regulation Act of 2022 (MOCRA), and other changes that were included as part of the December 2022 omnibus appropriations bill.
     
    CP: What types of pharmaceutical products are being recalled and what are these recalls attributed to?
     
    CH: There were 11 categories for which pharmaceutical products were recalled in 2022 including Current Good Manufacturing Practice (cGMP) deviations, contamination, failed specifications, leakage, and sterility. These categories applied to both prescription and over-the-counter (OTC) drugs and health products. 
     
    Accounting 83 of the 363 events and 437.5 million units – 77.1% of all pharmaceutical units recalled for the year – cGMP deviations was the most common reason for recalls in this sector. Impacted products included OTC pain relievers, a variety of hand sanitizers, antibiotic ointment and several brands and strengths of losartan potassium tablets.
     
    The FDA has the authority to waive some of the cGMP requirements for products that receive emergency use authorization (EUA), as many did during the COVID-19 public health emergency (PHE). As the PHE ends, there may be a further increase in cGMP violations. Smaller companies that started manufacturing products during the pandemic are less familiar with the strict requirements of cGMP. If they want to continue marketing products once the EUA period ends, they could face some tough challenges. 
     
    Sterility and failed specifications both accounted for 68 recalls each, making them the joint second reason for pharmaceutical recalls in 2022. Impacted products included sodium bicarbonate injections, magnesium citrate, eye drops, and allergy relief tablets. Despite both recording the same number of recall events, there were far more units recalled over sterility issues (96.1 million) than failed specifications (11.4 million). 
     
    CP: What are some key FDA reform changes can we expect to see?
     
    CH: One area to watch is cannabidiol (CBD), an active ingredient in cannabis. Despite being used in everything from foods to topical products, the FDA denied three citizen petitions requesting rulemaking to allow CBD products to be marketed as dietary supplements. The FDA determined it is not clear how these products could meet current safety standards and that a new regulatory pathway for CBD products was needed. 
     
    The agency also issued final guidance for using cannabis and cannabis-derived compounds in clinical research, detailing standards and requirements for investigational new drug applications.
     
    Another key area will be the FDA’s position on artificial intelligence (AI) in drug manufacturing. A discussion paper issued in March 2023 looked at possible applications and benefits. It also identified regulatory questions and asked for feedback in five areas such as the need for standards in developing and validating AI models used for process control and to support release testing.
     
    CP: How might changes to the FDA’s authority under the new Omnibus Reform Act affect pharmaceutical companies and contract manufacturers?
     
    CH: Pharmaceutical companies and contract manufacturers will be impacted by the FDA’s accelerated approval process for drugs and biologics. Under the Omnibus Reform Act, the FDA can require a post-approval study to be underway prior to granting accelerated approval for drugs and biologics. It also expands the agency’s current expedited withdrawal procedures and allows the use of accelerated procedures if a sponsor fails to conduct any required post-approval study of the product with due diligence. In fact, this failure, or the failure to submit timely reports for the product, would be considered prohibited acts under the Food, Drug & Cosmetics Act (FD&C Act). 
     
    Under the new accelerated approval provisions, sponsors must submit progress reports every 180 days for any post-approval study. These reports will be published on the FDA’s website. This transparency will create potential risk for sponsors if they fail to meet the schedule. 
     
    1.     https://marketing.sedgwick.com/acton/media/4952/us-sotn-2023-index-report-download-pr
     
    Chris Harvey is senior vice president of brand protection at Sedgwick. With 15 years’ experience, he is recognized as an expert in the recall industry and routinely speaks on best practices at trade shows, conventions, and conferences. Throughout his career, Chris has managed more than 1,200 recall and in-market remediations, including hundreds for the largest U.S. and global brands. He also serves on the board of directors of the International Consumer Product Health and Safety Organization (ICPHSO).
      Loading, Please Wait..
      Trending
      • Biopharma Layoffs In 1Q23
      • Lonza Acquires Synaffix For €100M
      • Traceability & 2D Barcodes
      • "3 Key Trends" With Harald Oberegger
      • 3M Invests $146M In Biopharma Filtration Technology
      Breaking News
      • Terran Biosciences, Pierre Fabre Ink Exclusive Licensing Deal for Idazoxan
      • ASM Research Chemicals Launches Development Packs for API Manufacturing
      • WuXi Increases Manufacturing Capacity in Germany
      • Quanticate, KPS Life Partner to Advance Clinical Research
      • Sterling Joins Partnership to Advance AI Flow Chemistry Techniques
      View Breaking News >
      CURRENT ISSUE

      May 2023

      • New Modalities Hog the Limelight
      • Cell and Gene Therapy is Coming of Age
      • Demand Surges for Cell and Gene Therapy Contract Manufacturing
      • Embracing a New Reality
      • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
      • Single-Use Technologies Enable Biologic Scaling
      • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
      • FTEs in Drug Discovery
      • Digital Transformation in Pharma
      • What is a Manufacturing Ecosystem and Why are They Growing?
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Stefan Pasiakos, PhD, Selected to Lead NIH Office of Dietary Supplements
      Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
      BGG Receives Patent for Saw Palmetto ID Method
      Coatings World

      Latest Breaking News From Coatings World

      Indorama Ventures and Carbios Reaffirm Partnership to Build PET Biorecycling Plant
      AkzoNobel Powder Coatings Enhances Digital Services with Launch of My Interpon Portal
      PPG Opens Color Creation Lab with Chery Automobile in China
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—June 3
      CardioRenal’s TENOR Device Receives Breakthrough Device Designation from FDA
      LifeQ Unveils New 24-Hour Sleep Solution
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Terran Biosciences, Pierre Fabre Ink Exclusive Licensing Deal for Idazoxan
      ASM Research Chemicals Launches Development Packs for API Manufacturing
      WuXi Increases Manufacturing Capacity in Germany
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      L'Oréal North Asia President Discusses China's Consumer Sector Recovery & Premium Beauty Trends
      Kiehl’s Celebrates Pride by Supporting The Trevor Project
      L’Oréal & UNESCO Announce 2023 Laureates of the For Women in Science International Awards
      Happi

      Latest Breaking News From Happi

      An Eco-Friendly & Stylish PET Dropper for Cosmetic Products New from Epopack
      Color Street Celebrates Pride Month with Limited-Edition ‘Over the Rainbow’ Nail Strips
      Olay Rolls Out Sensitive Skin Line
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: INX Digital, hubergroup and HP Top This Week’s Stories
      Mactac Acquires Canadian Roll Label Distributor Label Supply
      WestRock Advances its Commitment to a Sustainable Future
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Schreiner's Pharma-Comb IL Label supports clinical trial cancer medication
      First Anytron ANY-JET III digital label press installed in Korea
      FPA announces Kasie Fairbarn as elected ELC co-chair
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: KNH Launches Eco-Friendly Pads, Freudenberg Opens Apparel Competence Center & More
      Harper Hygienics Launches Hemp-Based Intimate Care Wipes
      What You’re Reading on Nonwovens-Industry.com
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most-Read Stories This Week—June 3
      Augmedics Debuts New Features, Indications for xvision Platform
      Artelon Closes $20M Series B Funding
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Francisco Melo, Smart Skis, onsemi Top This Week’s Stories
      DIC Acquires Photoresist Polymers Manufacturer PCAS Canada
      Arkema Collaborates with Habitat for Humanity Philadelphia

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login